Gene therapy for severe combined immunodeficiency: Are we there yet?

Journal of Clinical Investigation

Volumn 117, Issue 6, 2007, Pages 1456-1465

  Cavazzana Calvo, Marina ^a,b   Fischer, Alain ^b  

^a INSERM   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; ANTIVIRUS AGENT; CYCLIN DEPENDENT KINASE 2 INHIBITOR; GANCICLOVIR; HLA ANTIGEN CLASS 2; INTERLEUKIN 15 RECEPTOR; INTERLEUKIN 21 RECEPTOR; INTERLEUKIN 3; LENTIVIRUS VECTOR; LIM DOMAIN ONLY 2; ONCOPROTEIN; PARVOVIRUS VECTOR; PEGADENOSINE DEAMINASE; PROTEIN P16INK4A; PROTEIN P19; PROTEIN P53; PROTEIN RPE65; RECOMBINANT BLOOD CLOTTING FACTOR 9; RECOMBINANT DNA; RETROVIRUS VECTOR; T LYMPHOCYTE RECEPTOR; THYMIDINE KINASE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; ZINC FINGER PROTEIN;

ADENOSINE DEAMINASE DEFICIENCY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ASPERGILLOSIS; ASPERGILLUS; BLOOD CLOTTING FACTOR 10 DEFICIENCY; BURN; CARCINOGENESIS; COMBINED IMMUNODEFICIENCY; CYTOMEGALIC INCLUSION BODY DISEASE; CYTOMEGALOVIRUS; DOG; ENZYME DEFICIENCY; EPIDERMOLYSIS BULLOSA; GENE EXPRESSION REGULATION; GENE MUTATION; GENOTYPE; HEMOPHILIA B; HLA MATCHING; HUMAN; INTESTINE INFECTION; LEBER CONGENITAL AMAUROSIS; LYMPHOMA; MONKEY; MOUSE STRAIN; NONHUMAN; OMENN SYNDROME; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT INFECTION; RETINA DEGENERATION; REVIEW; SUICIDE GENE THERAPY; T LYMPHOCYTE; TRANSGENIC MOUSE; TYROSINEMIA; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS REPLICATION; WISKOTT ALDRICH SYNDROME; X CHROMOSOME LINKED DISORDER;

BONE MARROW TRANSPLANTATION; CLINICAL TRIALS; DNA REPAIR; GENE THERAPY; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MUTATION; RECOMBINATION, GENETIC; SAFETY; SEVERE COMBINED IMMUNODEFICIENCY; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 34249890562     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI30953     Document Type: Review

References (119)

1. Kay, M.A., Glorioso, J.C., and Naldini, L. 2001. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat. Med. 7:33-40.
2. Verma, I.M., and Weitzman, M.D. 2005. Gene therapy: twenty-first century medicine. Annu. Rev. Biochem. 74:711-738.
3. Jiang, H., et al. 2006. Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol. Ther. 14:452-455.
4. Lanuti, M., et al. 1999. Evaluation of an E1E4-deleted adenovirus expressing the herpes simplex thymidine kinase suicide gene in cancer gene therapy. Hum. Gene Ther. 10:463-475.
5. Manno, C.S., et al. 2003. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood. 101:2963-2972.
6. Antoine, C., et al. 2003. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968-99. Lancet. 361:553-560.
7. Gallico, G.G., 3rd, O'Connor, N.E., Compton, C.C., Kehinde, O., and Green, H. 1984. Permanent coverage of large burn wounds with autologous cultured human epithelium. N. Engl. J. Med. 311:448-451.
8. Brouard, M., and Barrandon, Y. 2003. Controlling skin morphogenesis: hope and despair. Curr. Opin. Biotechnol. 14:520-525.
9. Ferrari, S., Pellegrini, G., Matsui, T., Mavilio, F., and De Luca, M. 2006. Gene therapy in combination with tissue engineering to treat epidermolysis bullosa. Expert Opin. Biol. Ther. 6:367-378.
10. Mavilio, F., et al. 2006. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat. Med. 12:1397-1402.
11. Tenenbaum, L., et al. 2002. Neuroprotective gene therapy for Parkinson's disease. Curr. Gene Ther. 2:451-483.
12. Biffi, A., et al. 2006. Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. J. Clin. Invest. 116:3070-3082. doi:10.1172/JCI28873.
13. Bondanza, A., et al. 2006. Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. Blood. 107:1828-1836.
14. Acland, G.M., et al. 2001. Gene therapy restores vision in a canine model of childhood blindness. Nat. Genet. 28:92-95.
15. Bainbridge, J.W., Tan, M.H., and Ali, R.R. 2006. Gene therapy progress and prospects: the eye. Gene Ther. 13:1191-1197.
16. Kay, M.A., et al. 2000. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet. 24:257-261.
17. Mount, J.D., et al. 2002. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood. 99:2670-2676.
18. Manno, C.S., et al. 2006. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12:342-347.
19. Aubert, D., et al. 2002. Cytotoxic immune response blunts long-term transgene expression after efficient retroviral-mediated hepatic gene transfer in rat. Mol. Ther. 5:388-396.
20. Buckley, R.H. 2002. Primary immunodeficiency diseases: dissectors of the immune system. Immunol. Rev. 185:206-219.
21. Fischer, A. 2004. Human primary immunodeficiency diseases: a perspective. Nat. Immunol. 5:23-30.
22. Notarangelo, L.D., et al. 2000. Of genes and phenotypes: the immunological and molecular spectrum of combined immune deficiency. Defects of the gamma(c)-JAK3 signaling pathway as a model. Immunol. Rev. 178:39-48.
23. de Saint Basile, G., et al. 2004. Severe combined immunodeficiency caused by deficiency in either the delta or the epsilon subunit of CD3. J. Clin. Invest. 114:1512-1517. doi:10.1172/JCI200422588.
24. Rieux-Laucat, F., et al. 2006. Inherited and somatic CD3zeta mutations in a patient with T-cell deficiency. N. Engl. J. Med. 354:1913-1921.
25. Dadi, H.K., Simon, A.J., and Roifman, C.M. 2003. Effect of CD3delta deficiency on maturation of alpha/beta and gamma/delta T-cell lineages in severe combined immunodeficiency. N. Engl. J. Med. 349:1821-1828.
26. Kung, C., et al. 2000. Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease. Nat. Med. 6:343-345.
27. Elder, M.E., et al. 1995. Severe combined immunodeficiency with absence of peripheral blood CD8+ T cells due to ZAP-70 deficiency. Cell. Immunol. 165:110-117.
28. Arnaiz-Villena, A., et al. 1992. Brief report: primary immunodeficiency caused by mutations in the gene encoding the CD3-gamma subunit of the Tlymphocyte receptor. N. Engl. J. Med. 327:529-533.
29. Villard, J., Masternak, K., Lisowska-Grospierre, B., Fischer, A., and Reith, W. 2001. MHC class II deficiency: a disease of gene regulation. Medicine (Baltimore). 80:405-418.
30. Dror, Y., et al. 2004. Purine nucleoside phosphorylase deficiency associated with a dysplastic marrow morphology. Pediatr. Res. 55:472-477.
31. Buck, D., et al. 2006. Severe combined immunodeficiency and microcephaly in siblings with hypomorphic mutations in DNA ligase IV. Eur. J. Immunol. 36:224-235.
32. Buck, D., et al. 2006. Cernunnos, a novel nonhomologous end-joining factor, is mutated in human immunodeficiency with microcephaly. Cell. 124:287-299.
33. Villa, A., et al. 2001. V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations. Blood. 97:81-88.
34. Bach, F.H., Albertini, R.J., Joo, P., Anderson, J.L., and Bortin, M.M. 1968. Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome. Lancet. 2:1364-1366.
35. Gatti, R.A., Meuwissen, H.J., Allen, H.D., Hong, R., and Good, R.A. 1968. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet. 2:1366-1369.
36. Booth, C., et al. 2007. Management options for adenosine deaminase deficiency. In Proceedings of the EBMT Satellite Workshop. March 19-22, 2006. Hamburg, Germany. Clin. Immunol. 123:139-147.
37. Caillat-Zucman, S., et al. 2004. Impact of HLA matching on outcome of hematopoietic stem cell transplantation in children with inherited diseases: a single-center comparative analysis of genoidentical, haploidentical or unrelated donors. Bone Marrow Transplant. 33:1089-1095.
38. Grunebaum, E., et al. 2006. Bone marrow transplantation for severe combined immune deficiency. JAMA. 295:508-518.
39. Rao, K., et al. 2005. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood. 105:879-885.
40. Bertrand, Y., et al. 1999. Influence of severe combined immunodeficiency phenotype on the outcome of HLA non-identical, T-cell-depleted bone marrow transplantation: a retrospective European survey from the European Group for Bone Marrow Transplantation and the European Society for Immunodeficiency. J. Pediatr. 134:740-748.
41. Buckley, R.H., et al. 1999. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N. Engl. J. Med. 340:508-516.
42. Fischer, A., et al. 2005. Severe combined immunodeficiency. A model disease for molecular immunology and therapy. Immunol. Rev. 203:98-109.
43. Ouachee-Chardin, M., et al. 2006. Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single-center report of 48 patients. Pediatrics. 117:e743-e750.
44. Haddad, E., et al. 1998. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Blood. 91:3646-3653.
45. Cavazzana-Calvo, M., et al. 2007. Long-term T cell reconstitution after haematopoietic stem cell transplantation in primary T cell immunodeficient patients is associated with myeloid chimerism and possibly the primary disease phenotype. Blood. 109:4575-4581.
46. Jonkers, J., and Berns, A. 1996. Retroviral insertional mutagenesis as a strategy to identify cancer genes. Biochim. Biophys. Acta. 1287:29-57.
47. Nisole, S., and Saib, A. 2004. Early steps of retrovirus replicative cycle. Retrovirology. 1:9.
48. Naldini, L., et al. 1996. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 272:263-267.
49. Follenzi, A., Ailles, L.E., Bakovic, S., Geuna, M., and Naldini, L. 2000. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat. Genet. 25:217-222.
50. Zennou, V., et al. 2000. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell. 101:173-185.
51. Yu, S.F., et al. 1986. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 83:3194-3198.
52. Schambach, A., et al. 2006. Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. Mol. Ther. 13:391-400.
53. Zufferey, R., et al. 1998. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72:9873-9880.
54. Kahl, C.A., Marsh, J., Fyffe, J., Sanders, D.A., and Cornetta, K. 2004. Human immunodeficiency virus type 1-derived lentivirus vectors pseudotyped with envelope glycoproteins derived from Ross River virus and Semliki Forest virus. J. Virol. 78:1421-1430.
55. Yang, L., Bailey, L., Baltimore, D., and Wang, P. 2006. Targeting lentiviral vectors to specific cell types in vivo. Proc. Natl. Acad. Sci. U. S. A. 103:11479-11484.
56. Maurice, M., et al. 2002. Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide. Blood. 99:2342-2350.
57. Kobinger, G.P., Weiner, D.J., Yu, Q.C., and Wilson, J.M. 2001. Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat. Biotechnol. 19:225-230.
58. Hofmann, S.R., et al. 2002. Cytokines and their role in lymphoid development, differentiation and homeostasis. Curr. Opin. Allergy Clin. Immunol. 2:495-506.
59. Cavazzana-Calvo, M., Lagresle, C., Hacein-Bey-Abina, S., and Fischer, A. 2005. Gene therapy for severe combined immunodeficiency. Annu. Rev. Med. 56:585-602.
60. Gaspar, B., et al. 2004. Successful gene therapy of SCID-X1 using a pseudotyped gammaretroviral vector. Lancet. 364:2181-2187.
61. Gaspar, H.B., et al. 2006. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol. Ther. 14:505-513.
62. Aiuti, A., et al. 2002. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science. 296:2410-2413.
63. Hirschhorn, R., et al. 1996. Spontaneous in vivo reversion to normal of an inherited mutation in a patient with adenosine deaminase deficiency. Nat. Genet. 13:290-295.
64. Bousso, P., et al. 2000. Diversity, functionality, and stability of the T cell repertoire derived in vivo from a single human T cell precursor. Proc. Natl. Acad. Sci. U. S. A. 97:274-278.
65. Wada, T., et al. 2001. Somatic mosaicism in Wiskott-Aldrich syndrome suggests in vivo reversion by a DNA slippage mechanism. Proc. Natl. Acad. Sci. U. S. A. 98:8697-8702.
66. Konno, A., et al. 2004. Differential contribution of Wiskott-Aldrich syndrome protein to selective advantage in T- and B-cell lineages. Blood. 103:676-678.
67. Hirschhorn, R. 2003. In vivo reversion to normal of inherited mutations in humans. J. Med. Genet. 40:721-728.
68. Stephan, V., et al. 1996. Atypical X-linked severe combined immunodeficiency due to possible spontaneous reversion of the genetic defect in T cells. N. Engl. J. Med. 335:1563-1567.
69. Cavazzana-Calvo, M., et al. 2000. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 288:669-672.
70. Schmidt, M., et al. 2005. Clonal evidence for the transduction of CD34+ cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial. Blood. 105:2699-2706.
71. Kohn, D.B., et al. 1998. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat. Med. 4:775-780.
72. Deichmann, A., et al. 2007. Vector integration is non-random, clustered, and influences the in vivo fate of lymphopoiesis in SCID-X1 gene therapy. J. Clin. Invest. In press.
73. Ott, M.G., et al. 2006. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 12:401-409.
74. Lewinski, M.K., et al. 2006. Retroviral DNA integration: viral and cellular determinants of target-site selection. PLoS Pathog. 2:e60.
75. Thrasher, A.J., et al. 2005. Failure of SCID-X1 gene therapy in older patients. Blood. 105:4255-4257.
76. Robbins, P.B., et al. 1998. Consistent, persistent expression from modified retroviral vectors in murine hematopoietic stem cells. Proc. Natl. Acad. Sci. U. S. A. 95:10182-10187.
77. Hacein-Bey-Abina, S., et al. 2003. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 302:415-419.
78. Cornetta, K., Morgan, R.A., and Anderson, W.F. 1991. Safety issues related to retroviral-mediated gene transfer in humans. Hum. Gene Ther. 2:5-14.
79. Kohn, D.B., Sadelain, M., and Glorioso, J.C. 2003. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat. Rev. Cancer. 3:477-488.
80. McCormack, M.P., and Rabbitts, T.H. 2004. Mechanisms of disease: activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 350:913-922.
81. Boehm, T., Foroni, L., Kaneko, Y., Perutz, M.F., and Rabbitts, T.H. 1991. The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13. Proc. Natl. Acad. Sci. U. S. A. 88:4367-4371.
82. Larson, R.C., Osada, H., Larson, T.A., Lavenir, I., and Rabbitts, T.H. 1995. The oncogenic LIM protein Rbtn2 causes thymic developmental aberrations that precede malignancy in transgenic mice. Oncogene. 11:853-862.
83. Royer-Pokora, B., Loos, U., and Ludwig, W.D. 1991. TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11). Oncogene. 6:1887-1893.
84. Dave, U.P., Jenkins, N.A., and Copeland, N.G. 2004. Gene therapy insertional mutagenesis insights. Science. 303:333.
85. Kelly, P.F., Vandergriff, J., Nathwani, A., Nienhuis, A.W., and Vanin, E.F. 2000. Highly efficient gene transfer into cord blood nonobese diabetic/severe combined immunodeficiency repopulating cells by oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114) envelope protein. Blood. 96:1206-1214.
86. Woods, N.B., Bottero, V., Schmidt, M., von Kalle, C., and Verma, I.M. 2006. Gene therapy: therapeutic gene causing lymphoma. Nature. 440:1123.
87. Thrasher, A.J., et al. 2006. Gene therapy: X-SCID transgene leukaemogenicity. Nature. 443:E5-E6; discussion E6-E7.
88. Kustikova, O., et al. 2005. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science. 308:1171-1174.
89. Shou, Y., Ma, Z., Lu, T., and Sorrentino, B.P. 2006. Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. Proc. Natl. Acad. Sci. U. S. A. 103:11730-11735.
90. Montini, E., et al. 2006. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol. 24:687-696.
91. Sherr, C.J. 2004. Principles of tumor suppression. Cell. 116:235-246.
92. West, A.G., Gaszner, M., and Felsenfeld, G. 2002. Insulators: many functions, many mechanisms. Genes Dev. 16:271-288.
93. Gaszner, M., and Felsenfeld, G. 2006. Insulators: exploiting transcriptional and epigenetic mechanisms. Nat. Rev. Genet. 7:703-713.
94. Bank, A., Dorazio, R., and Leboulch, P. 2005. A phase I/II clinical trial of beta-globin gene therapy for beta-thalassemia. Ann. N. Y. Acad. Sci. 1054:308-316.
95. Ellis, J., and Yao, S. 2005. Retrovirus silencing and vector design: relevance to normal and cancer stem cells? Curr. Gene Ther. 5:367-373.
96. Emery, D.W., et al. 2002. Development of virus vectors for gene therapy of beta chain hemoglobinopathies: flanking with a chromatin insulator reduces gamma-globin gene silencing in vivo. Blood. 100:2012-2019.
97. Puthenveetil, G., et al. 2004. Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector. Blood. 104:3445-3453.
98. Litvinova, E., et al. 2002. Graft-versus-leukemia effect after suicide-gene-mediated control of graft-versus-host disease. Blood. 100:2020-2025.
99. Tiberghien, P., et al. 2001. Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood. 97:63-72.
100. Olivares, E.C., et al. 2002. Site-specific genomic integration produces therapeutic Factor IX levels in mice. Nat. Biotechnol. 20:1124-1128.
101. Sclimenti, C.R., Thyagarajan, B., and Calos, M.P. 2001. Directed evolution of a recombinase for improved genomic integration at a native human sequence. Nucleic Acids Res. 29:5044-5051.
102. Groth, A.C., Olivares, E.C., Thyagarajan, B., and Calos, M.P. 2000. A phage integrase directs efficient site-specific integration in human cells. Proc. Natl. Acad. Sci. U. S. A. 97:5995-6000.
103. Held, P.K., et al. 2005. In vivo correction of murine hereditary tyrosinemia type I by phiC31 integrase-mediated gene delivery. Mol. Ther. 11:399-408.
104. Ortiz-Urda, S., et al. 2002. Stable nonviral genetic correction of inherited human skin disease. Nat. Med. 8:1166-1170.
105. Ishikawa, Y., et al. 2006. Phage phiC31 integrase-mediated genomic integration of the common cytokine receptor gamma chain in human T-cell lines. J. Gene Med. 8:646-653.
106. Junop, M.S., and Haniford, D.B. 1997. Factors responsible for target site selection in Tn10 transposition: a role for the DDE motif in target DNA capture. EMBO J. 16:2646-2655.
107. Appa, R.S., Shin, C.G., Lee, P., and Chow, S.A. 2001. Role of the nonspecific DNA-binding region and alpha helices within the core domain of retroviral integrase in selecting target DNA sites for integration. J. Biol. Chem. 276:45848-45855.
108. Lu, R., Ghory, H.Z., and Engelman, A. 2005. Genetic analyses of conserved residues in the carboxyl-terminal domain of human immunodeficiency virus type 1 integrase. J. Virol. 79:10356-10368.
109. Goulaouic, H., and Chow, S.A. 1996. Directed integration of viral DNA mediated by fusion proteins consisting of human immunodeficiency virus type 1 integrase and Escherichia coli LexA protein. J. Virol. 70:37-46.
110. Schroder, A.R., et al. 2002. HIV-1 integration in the human genome favors active genes and local hotspots. Cell. 110:521-529.
111. Kim, Y.G., Li, L., and Chandrasegaran, S. 1994. Insertion and deletion mutants of FokI restriction endonuclease. J. Biol. Chem. 269:31978-31982.
112. Rouet, P., Smih, F., and Jasin, M. 1994. Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 91:6064-6068.
113. Choulika, A., Perrin, A., Dujon, B., and Nicolas, J.F. 1995. Induction of homologous recombination in mammalian chromosomes by using the I-SceI system of Saccharomyces cerevisiae. Mol. Cell. Biol. 15:1968-1973.
114. Sargent, R.G., Brenneman, M.A., and Wilson, J.H. 1997. Repair of site-specific double-strand breaks in a mammalian chromosome by homologous and illegitimate recombination. Mol. Cell. Biol. 17:267-277.
115. Bibikova, M., Beumer, K., Trautman, J.K., and Carroll, D. 2003. Enhancing gene targeting with designed zinc finger nucleases. Science. 300:764.
116. Porteus, M.H., Cathomen, T., Weitzman, M.D., and Baltimore, D. 2003. Efficient gene targeting mediated by adeno-associated virus and DNA doublestrand breaks. Mol. Cell. Biol. 23:3558-3565.
117. Urnov, F.D., et al. 2005. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature. 435:646-651.
118. Ehrhardt, A., Xu, H., Huang, Z., Engler, J.A., and Kay, M.A. 2005. A direct comparison of two nonviral gene therapy vectors for somatic integration: in vivo evaluation of the bacteriophage integrase phiC31 and the Sleeping Beauty transposase. Mol. Ther. 11:695-706.
119. Kaiser, J. 2005. Gene therapy. Putting the fingers on gene repair. Science. 310:1894-1896.